Viking Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Viking Therapeutics, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors, ratify auditors, and approve executive compensation.
NASDAQ
Viking Therapeutics will hold its annual stockholder meeting virtually on May 20, 2025, to vote on director elections, auditor ratification, and executive compensation.
NASDAQ
DEFR14A: Viking Therapeutics Seeks Stockholder Approval for CBIZ CPAs P.C. Appointment at 2025 Annual Meeting
Viking Therapeutics files an amendment to its proxy statement to reflect the appointment of CBIZ CPAs P.C. as the new independent registered public accounting firm for the fiscal year ending December 31, 2025, following Marcum LLP's resignation.
NASDAQ
Viking Therapeutics will hold its annual stockholder meeting virtually on June 13, 2023, to vote on director elections, auditor ratification, executive compensation, and an amendment to the company's certificate of incorporation.
NASDAQ
Viking Therapeutics will hold its annual stockholders meeting virtually on May 20, 2025, to vote on director elections, auditor ratification, and executive compensation.
NASDAQ
Viking Therapeutics will hold its annual stockholder meeting virtually on June 13, 2023, to vote on director elections, auditor ratification, executive compensation, and an amendment to the company's certificate of incorporation.
NASDAQ
Viking Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on May 21, 2024, outlining proposals for director elections, auditor ratification, executive compensation, and equity incentive plans.